Management of borderline resectable pancreatic adenocarcinoma

Yuxia Jia, Tony J.C. Wang, John Allendorf, Muhammad Wasif Saif

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men and women. Despite much effort in translational research, pancreatic adenocarcinoma remains a challenging disease with an overall 5-year survival rate less than 5%. To date, the only potentially curative treatment for managing pancreatic adenocarcinoma is surgical resection. However, more than 80% of patients are deemed either unresectable or metastatic upon diagnosis. For borderline resectable disease, although there is no high-level evidence supporting its use, an initial approach involving neoadjuvant therapy is preferred, as opposed to immediate surgery. In this year's ASCO Gastrointestinal Cancers Symposium, several studies were presented with approaches towards treating borderline resectable pancreatic adenocarcinoma. Retrospective studies (Abstract #280, #304, #327) were presented and showed that neoadjuvant chemoradiation were associated with higher rates of negative margin resection and better survival. The tolerability of accelerated fraction radiotherapy with concomitant capecitabine was demonstrated in a phase I study (Abstract #329). More effective therapeutic approaches and prospective studies are needed for this devastating illness. This highlight article will focus on the management of borderline resectable pancreatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)147-150
Number of pages4
JournalJournal of the Pancreas
Volume13
Issue number2
StatePublished - Mar 26 2012

Fingerprint

Adenocarcinoma
Neoadjuvant Therapy
Gastrointestinal Neoplasms
Translational Medical Research
Radiotherapy
Survival Rate
Retrospective Studies
Prospective Studies
Survival
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Jia, Y., Wang, T. J. C., Allendorf, J., & Saif, M. W. (2012). Management of borderline resectable pancreatic adenocarcinoma. Journal of the Pancreas, 13(2), 147-150.
Jia, Yuxia ; Wang, Tony J.C. ; Allendorf, John ; Saif, Muhammad Wasif. / Management of borderline resectable pancreatic adenocarcinoma. In: Journal of the Pancreas. 2012 ; Vol. 13, No. 2. pp. 147-150.
@article{88401410580547f7a3aaddd822e08af2,
title = "Management of borderline resectable pancreatic adenocarcinoma",
abstract = "Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men and women. Despite much effort in translational research, pancreatic adenocarcinoma remains a challenging disease with an overall 5-year survival rate less than 5{\%}. To date, the only potentially curative treatment for managing pancreatic adenocarcinoma is surgical resection. However, more than 80{\%} of patients are deemed either unresectable or metastatic upon diagnosis. For borderline resectable disease, although there is no high-level evidence supporting its use, an initial approach involving neoadjuvant therapy is preferred, as opposed to immediate surgery. In this year's ASCO Gastrointestinal Cancers Symposium, several studies were presented with approaches towards treating borderline resectable pancreatic adenocarcinoma. Retrospective studies (Abstract #280, #304, #327) were presented and showed that neoadjuvant chemoradiation were associated with higher rates of negative margin resection and better survival. The tolerability of accelerated fraction radiotherapy with concomitant capecitabine was demonstrated in a phase I study (Abstract #329). More effective therapeutic approaches and prospective studies are needed for this devastating illness. This highlight article will focus on the management of borderline resectable pancreatic adenocarcinoma.",
author = "Yuxia Jia and Wang, {Tony J.C.} and John Allendorf and Saif, {Muhammad Wasif}",
year = "2012",
month = "3",
day = "26",
language = "English (US)",
volume = "13",
pages = "147--150",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "2",

}

Jia, Y, Wang, TJC, Allendorf, J & Saif, MW 2012, 'Management of borderline resectable pancreatic adenocarcinoma', Journal of the Pancreas, vol. 13, no. 2, pp. 147-150.

Management of borderline resectable pancreatic adenocarcinoma. / Jia, Yuxia; Wang, Tony J.C.; Allendorf, John; Saif, Muhammad Wasif.

In: Journal of the Pancreas, Vol. 13, No. 2, 26.03.2012, p. 147-150.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Management of borderline resectable pancreatic adenocarcinoma

AU - Jia, Yuxia

AU - Wang, Tony J.C.

AU - Allendorf, John

AU - Saif, Muhammad Wasif

PY - 2012/3/26

Y1 - 2012/3/26

N2 - Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men and women. Despite much effort in translational research, pancreatic adenocarcinoma remains a challenging disease with an overall 5-year survival rate less than 5%. To date, the only potentially curative treatment for managing pancreatic adenocarcinoma is surgical resection. However, more than 80% of patients are deemed either unresectable or metastatic upon diagnosis. For borderline resectable disease, although there is no high-level evidence supporting its use, an initial approach involving neoadjuvant therapy is preferred, as opposed to immediate surgery. In this year's ASCO Gastrointestinal Cancers Symposium, several studies were presented with approaches towards treating borderline resectable pancreatic adenocarcinoma. Retrospective studies (Abstract #280, #304, #327) were presented and showed that neoadjuvant chemoradiation were associated with higher rates of negative margin resection and better survival. The tolerability of accelerated fraction radiotherapy with concomitant capecitabine was demonstrated in a phase I study (Abstract #329). More effective therapeutic approaches and prospective studies are needed for this devastating illness. This highlight article will focus on the management of borderline resectable pancreatic adenocarcinoma.

AB - Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men and women. Despite much effort in translational research, pancreatic adenocarcinoma remains a challenging disease with an overall 5-year survival rate less than 5%. To date, the only potentially curative treatment for managing pancreatic adenocarcinoma is surgical resection. However, more than 80% of patients are deemed either unresectable or metastatic upon diagnosis. For borderline resectable disease, although there is no high-level evidence supporting its use, an initial approach involving neoadjuvant therapy is preferred, as opposed to immediate surgery. In this year's ASCO Gastrointestinal Cancers Symposium, several studies were presented with approaches towards treating borderline resectable pancreatic adenocarcinoma. Retrospective studies (Abstract #280, #304, #327) were presented and showed that neoadjuvant chemoradiation were associated with higher rates of negative margin resection and better survival. The tolerability of accelerated fraction radiotherapy with concomitant capecitabine was demonstrated in a phase I study (Abstract #329). More effective therapeutic approaches and prospective studies are needed for this devastating illness. This highlight article will focus on the management of borderline resectable pancreatic adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84863352592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863352592&partnerID=8YFLogxK

M3 - Article

C2 - 22406587

AN - SCOPUS:84863352592

VL - 13

SP - 147

EP - 150

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 2

ER -

Jia Y, Wang TJC, Allendorf J, Saif MW. Management of borderline resectable pancreatic adenocarcinoma. Journal of the Pancreas. 2012 Mar 26;13(2):147-150.